



Citations and References

Complex Clinical Decisions Podcast Series

SAMHSA's Recovery to Practice (RTP) Clinical Decision Support CME courses offer timely, recovery-oriented information on prescribing and practices for physicians and other clinicians treating people with serious mental illness. The Complex Clinical Decisions podcast series explores challenging scenarios in psychopharmacology from a strength-based, recovery-oriented perspective, with a focus on shared decision-making, relationship building, and scientific and clinical evidence.

Citations and Resources for More Information

More Than One: Considering Multiple Medications in a Recovery Plan

Essock, S.M., Schooler, N.R., Stroup, T.S., McEvoy, J.P., Rojas, I., Jackson C., Covell N.H. (2011). Effectiveness of switching from antipsychotic polypharmacy to monotherapy. *American Journal of Psychiatry* 168(7): 702-708. doi: 10.1176/appi.ajp.2011.

Gallego, J.A., Bonetti, J., Zhang, J., Kane, J.M., & Correll, C.U. (2012). Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. *Schizophr Res*, 138(1), 18-28. doi: 10.1016/j.schres.2012.03.018.

Galling, B., Vernon, J.A., Pagsberg, A.K., et al. (2018). Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. *Acta Psychiatr Scand.*, 137(3):187-205. doi: 10.1111/acps.12854

Gupta S., Cahill J.D. (2016). A Prescription for "Deprescribing" in Psychiatry. *Psychiatr Serv*, 67(8):904-7. doi: 10.1176/appi.ps.201500359.

Helfer, B., Samara, M.T., Huhn, M., Klupp, E., Leucht, C., Zhu, Y., Engel, R.R., & Leucht, S. (2016). Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. *The American journal of psychiatry*, 173(9):876-886. doi: 10.1176/appi.ajp.2016.15081035

Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 45(9):789-796.

Lee, R.D. (1998). Polypharmacy: a case report and new protocol for management. *J Am Board Fam Pract*, 11(2):140-4.

Leucht, S., Helfer, B., Dold, M., Kissling, W., & McGrath, J. (2014). Carbamazepine for schizophrenia. *Cochrane Database Syst Rev.*, 5(CD001258). doi:10.1002/14651858.CD001258.pub3.

Leucht, S., Helfer, B., Dold, M., Kissling, W., & McGrath, J.J. (2015). Lithium for schizophrenia. *Cochrane Database Syst Rev.*, 10(CD003834). doi:10.1002/14651858.CD003834.pub3.

Olfson, M., Marcus, S.C., & Wan, G.J. (2009). Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. *Psychiatric services*, 60(2), 210-216. doi: 10.1176/ps.2009.60.2.210

Patient-centered outcomes research institute (PCORI). [Research study summary: [Comparative Effectiveness of Adaptive Pharmacotherapy Strategies for Schizophrenia](#).] Accessed April 20, 2018.

Premkumar, T.S., Pick, J. (2006). Lamotrigine for schizophrenia. *Cochrane Database Syst Rev.*, 4(CD005962). doi: 10.1002/14651858.CD005962.pub2.

Reeve E., Wiese, M.D. (2014). Benefits of deprescribing on patients' adherence to medications. *Int J Clin Pharm.*, 36(1):26-9. doi: 10.1007/s11096-013-9871-z.

Stroup, T.S., Gerhard, T., Crystal, S., Huang, C., Olfson, M. (2016). Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. *American Journal of Psychiatry*, 173(2):166-173. doi: 10.1176/appi.ajp.2015.15030332.

Thompson, A., Sullivan, S. A., Barley, M. et al. (2008). The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards – a cluster randomized controlled trial. *Psychological Medicine*, 38(5): 705-715. doi:10.1017/S003329170700147X

Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., & Tanskanen, A. (2016). Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study. *Am J Psychiatry*, 173(6):600-606. doi: 10.1176/appi.ajp.2015.15050618.

Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E. (2008) Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. *Drug Saf* 31: 7–20. <https://doi.org/10.2165/00002018-200831010-00002>

Trauer, J.M., Qian, M.Y., Doyle, J.S., Rajaratnam, S.M.W., & Cunnington, D. (2015). Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. *Ann Intern Med.*, 163:191-204. doi:10.7326/M14-2841.

Wang, Y., Xia, J., Helfer, B., Li, C., & Leucht, S. (2016). Valproate for schizophrenia. *Cochrane Database of Systematic Reviews*, 11(CD004028). doi: 10.1002/14651858.CD004028.pub4.

Werder, S.F., Preskorn, S.H. (2003). Managing polypharmacy: walking the fine line between help and harm. *Curr Psychiatry* 2:24–36.

Zhang, J.P., & Malhotra A.K. (2017). Pharmacogenomics of Antipsychotic Drugs. *Curr Treat Options Psych*, 4: 127. <https://doi.org/10.1007/s40501-017-0113-1>.